Today’s guest on The Long Run podcast is Ankit Mahadevia. Mahadevia is the CEO of Cambridge, Mass.-based Spero Therapeutics. It’s an antibiotic developer. Specifically, it’s focused on new strategies for fighting gram-negative bacterial infections that are increasingly resistant to our existing set of antibiotics. Despite persistent warnings from global health authorities about the rise of multi-drug resistant bugs, and the...Read More
Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.